One huge issue that I believe a majority of stock holders are over looking is that this is a first in class drug. Yes we are all impatient and want to file now. But these trials are about more than if a tan will protect the EPP patients. They have to prove on system wide scale that this first in class molecule does not effect any other systems negatively. We all know that ndp-msh is known to have anti-inflammitory, anti-pyretic properties and this would appear to be a great side effect. but they must also demonstrate that this cytokine and IL supression side effect will not mask the hallmark inflamation that indicates that something is truely wrong with a person, which normally be noticed through the indication of inflammation. point being, since there is no other drugs of this type they have to generate 100% of thier own clinical and scientific evidence, then systematically and system specifically prove it is safe AND effective.
CUV Price at posting:
$2.15 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)